Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents.
5-azanucleosides
DNA demethylating agents
DNA methylation
epigenetics
leukemia
Journal
Epigenomes
ISSN: 2075-4655
Titre abrégé: Epigenomes
Pays: Switzerland
ID NLM: 101736595
Informations de publication
Date de publication:
05 Jul 2023
05 Jul 2023
Historique:
received:
06
06
2023
revised:
28
06
2023
accepted:
01
07
2023
medline:
25
7
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
epublish
Résumé
Azanucleosides, such as 5-azacytidine and decitabine, are DNA demethylating agents used in the treatment of acute myeloid leukemia and myelodysplastic syndromes. Researchers continue to explore their utility in the treatment of other hematologic and solid tumors. Based on the capacity of the compounds to inhibit DNA methyltransferase enzymes and the important role of DNA methylation in health and disease, it is essential to understand the molecular changes that azanucleosides induce and how these changes may improve treatment outcomes in subsets of patients. This review summarizes the molecular and therapeutic actions of azanucleosides and discusses recent clinical trials of these compounds as single agents or in combination therapy for the treatment of cancer and related conditions.
Identifiants
pubmed: 37489400
pii: epigenomes7030012
doi: 10.3390/epigenomes7030012
pmc: PMC10366911
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NIGMS NIH HHS
ID : P20GM103434
Pays : United States
Références
Int J Biol Sci. 2015 Apr 08;11(5):604-17
pubmed: 25892967
Blood Adv. 2021 Apr 27;5(8):2264-2271
pubmed: 33904891
Clin Cancer Res. 2018 Jul 1;24(13):3163-3175
pubmed: 29615458
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):14-20
pubmed: 25696830
Biochim Biophys Acta. 2007 Jan;1775(1):138-62
pubmed: 17045745
J Clin Oncol. 2000 Mar;18(5):956-62
pubmed: 10694544
Lancet Oncol. 2017 Oct;18(10):1317-1326
pubmed: 28844816
Cell Stem Cell. 2013 Mar 7;12(3):329-41
pubmed: 23333149
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Epigenomics. 2015 Oct;7(7):1083-8
pubmed: 26541345
J Clin Oncol. 2014 Aug 20;32(24):2541-52
pubmed: 25071138
Cancer. 2015 Jul 15;121(14):2375-82
pubmed: 25809968
J Clin Oncol. 2002 May 15;20(10):2429-40
pubmed: 12011120
Onco Targets Ther. 2010 Jun 24;3:1-13
pubmed: 20616953
Clin Epigenetics. 2022 Jan 6;14(1):3
pubmed: 34991708
Haematologica. 2019 Aug;104(8):1565-1571
pubmed: 30733271
Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28
pubmed: 16829982
Drugs. 2021 Jan;81(1):179
pubmed: 33369722
Leukemia. 2014 Aug;28(8):1657-65
pubmed: 24451410
Clin Epigenetics. 2021 Aug 27;13(1):166
pubmed: 34452630
Pathobiology. 2019;86(1):7-13
pubmed: 30041243
Mol Reprod Dev. 2010 Feb;77(2):105-13
pubmed: 19921744
Epigenomics. 2010 Oct;2(5):657-69
pubmed: 21339843
Am J Hematol. 1993 Aug;43(4):286-90
pubmed: 7690519
Epigenetics Chromatin. 2017 May 8;10:23
pubmed: 28503201
Leukemia. 1993 May;7 Suppl 1:30-5
pubmed: 7683354
Blood. 2011 Sep 8;118(10):2708-11
pubmed: 21700776
Cancer Chemother Rep. 1973 Sep-Oct;57(3):319-23
pubmed: 4127393
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8
pubmed: 20368434
Expert Rev Anticancer Ther. 2009 Jul;9(7):875-84
pubmed: 19589026
Haematologica. 2010 Feb;95(2):303-10
pubmed: 19773261
Drugs Future. 2013 Aug;38(8):535-543
pubmed: 26190889
Oncotarget. 2015 Jun 10;6(16):13922-32
pubmed: 26015403
Leuk Res. 2015 Feb;39(2):183-91
pubmed: 25577399
J Clin Oncol. 2021 May 10;39(14):1584-1594
pubmed: 33449813
Blood. 2019 Mar 7;133(10):1096-1107
pubmed: 30670446
Cancer. 2006 Apr 15;106(8):1794-803
pubmed: 16532500
Oncologist. 2013;18(5):619-24
pubmed: 23671007
Cells. 2022 Aug 19;11(16):
pubmed: 36010665
J Clin Oncol. 2006 Aug 20;24(24):3895-903
pubmed: 16921040
Int J Cancer. 2011 Jun 15;128(12):2911-22
pubmed: 20960460
Cancer. 1981 Apr 1;47(7):1739-42
pubmed: 6164472
Cancer Res. 2016 Jun 1;76(11):3224-35
pubmed: 27197203
BMC Biol. 2015 Jan 31;13:7
pubmed: 25637097
J Clin Med. 2021 May 13;10(10):
pubmed: 34068316
Int J Cancer. 2008 Jul 1;123(1):8-13
pubmed: 18425818
Clin Cancer Res. 2020 Mar 1;26(5):1009-1016
pubmed: 31831561
Cancer Cell. 2018 Nov 12;34(5):724-740.e4
pubmed: 30423294
Drug Des Devel Ther. 2010 Sep 24;4:221-9
pubmed: 20957213
Cancer. 2006 Mar 1;106(5):1090-8
pubmed: 16435386
Epigenetics. 2019 Dec;14(12):1141-1163
pubmed: 31284823
Essays Biochem. 2020 Oct 26;64(5):687-703
pubmed: 32808652
Clin Epigenetics. 2016 Jun 21;8:71
pubmed: 27330573
Neuropsychopharmacology. 2013 Jan;38(1):23-38
pubmed: 22781841
Science. 2001 Aug 10;293(5532):1089-93
pubmed: 11498579
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):6796-9
pubmed: 25368180
Int J Mol Sci. 2021 Apr 19;22(8):
pubmed: 33921911
Pharmacol Ther. 2020 Jan;205:107416
pubmed: 31626871
Blood Adv. 2020 Mar 10;4(5):970-982
pubmed: 32150613
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Am J Transl Res. 2011 Feb;3(2):166-79
pubmed: 21416059
Chem Pharm Bull (Tokyo). 2022 Jul 1;70(7):469-476
pubmed: 35753803
Cold Spring Harb Perspect Med. 2017 May 1;7(5):
pubmed: 28159832
Ann Oncol. 2013 Apr;24(4):1112-9
pubmed: 23172636
Blood. 2017 Sep 28;130(13):1514-1522
pubmed: 28774880
Future Oncol. 2021 Jun;17(16):2077-2087
pubmed: 33709786
Blood Adv. 2021 Mar 9;5(5):1250-1258
pubmed: 33646303
Cancer. 2018 Jan 15;124(2):325-334
pubmed: 29211308
Curr Oncol Rep. 2019 Mar 23;21(4):37
pubmed: 30904967
Epigenomics. 2009 Oct;1(1):81-98
pubmed: 22122638
Mol Cancer Ther. 2010 May;9(5):1443-50
pubmed: 20442312
Oncotarget. 2017 Jun 20;8(25):41498-41507
pubmed: 28489568
Pharmacol Ther. 2018 Aug;188:45-79
pubmed: 29454856
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Pharmaceuticals (Basel). 2010 Jul 02;3(7):2022-2044
pubmed: 27713340
Blood. 1976 Sep;48(3):331-7
pubmed: 60156
Lancet Oncol. 2015 Sep;16(9):1099-1110
pubmed: 26296954